Summary by Moomoo AI
NeuroSense Therapeutics Ltd., a biotechnology firm specializing in treatments for neurodegenerative diseases, announced on February 7, 2024, that it has regained compliance with the NASDAQ Minimum Bid Price Rule. The company's ordinary shares maintained a closing bid price of $1.00 or more for at least 10 consecutive business days, satisfying the NASDAQ Listing Rule 5550(a)(2) requirement. This achievement closes the previous bid price deficiency issue. CEO Alon Ben-Noon highlighted the significance of this compliance in the context of the company's ongoing development of PrimeC, especially following promising results from the Phase 2b PARADIGM trial. NeuroSense is also anticipating the release of results from its collaboration with Biogen on the impact of PrimeC on neurofilament levels in PARADIGM participants. The company is focused on addressing the unmet medical needs of neurodegenerative diseases such as ALS, Alzheimer's, and Parkinson's through combined therapies targeting multiple disease pathways.